[HTML][HTML] Optimal biological dose: a systematic review in cancer phase I clinical trials
J Fraisse, D Dinart, D Tosi, C Bellera, C Mollevi - BMC cancer, 2021 - Springer
J Fraisse, D Dinart, D Tosi, C Bellera, C Mollevi
BMC cancer, 2021•SpringerBackground Classical phase 1 dose-finding designs based on a single toxicity endpoint to
assess the maximum tolerated dose were initially developed in the context of cytotoxic
drugs. With the emergence of molecular targeted agents and immunotherapies, the concept
of optimal biological dose (OBD) was subsequently introduced to account for efficacy in
addition to toxicity. The objective was therefore to provide an overview of published phase 1
cancer clinical trials relying on the concept of OBD. Methods We performed a systematic …
assess the maximum tolerated dose were initially developed in the context of cytotoxic
drugs. With the emergence of molecular targeted agents and immunotherapies, the concept
of optimal biological dose (OBD) was subsequently introduced to account for efficacy in
addition to toxicity. The objective was therefore to provide an overview of published phase 1
cancer clinical trials relying on the concept of OBD. Methods We performed a systematic …
Background
Classical phase 1 dose-finding designs based on a single toxicity endpoint to assess the maximum tolerated dose were initially developed in the context of cytotoxic drugs. With the emergence of molecular targeted agents and immunotherapies, the concept of optimal biological dose (OBD) was subsequently introduced to account for efficacy in addition to toxicity. The objective was therefore to provide an overview of published phase 1 cancer clinical trials relying on the concept of OBD.
Methods
We performed a systematic review through a computerized search of the MEDLINE database to identify early phase cancer clinical trials that relied on OBD. Relevant publications were selected based on a two-step process by two independent readers. Relevant information (phase, type of therapeutic agents, objectives, endpoints and dose-finding design) were collected.
Results
We retrieved 37 articles. OBD was clearly mentioned as a trial objective (primary or secondary) for 22 articles and was traditionally defined as the smallest dose maximizing an efficacy criterion such as biological target: biological response, immune cells count for immunotherapies, or biological cell count for targeted therapies. Most trials considered a binary toxicity endpoint defined in terms of the proportion of patients who experienced a dose-limiting toxicity. Only two articles relied on an adaptive dose escalation design.
Conclusions
In practice, OBD should be a primary objective for the assessment of the recommended phase 2 dose (RP2D) for a targeted therapy or immunotherapy phase I cancer trial. Dose escalation designs have to be adapted accordingly to account for both efficacy and toxicity.
Springer